Literature DB >> 12147799

C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients.

Kaj Jørgensen1, Johan Povlsen, Søren Madsen, Melvin Madsen, Hans Hansen, Asger Pedersen, Else-Marie Heinsvig, Jørgen Poulsen.   

Abstract

BACKGROUND: Recently, 2-h samples (C2) have been found superior to trough levels for therapeutic monitoring of transplanted patients receiving cyclosporin. The present study was undertaken to see if the same was the case for tacrolimus.
METHODS: Blood tacrolimus levels were determined in 21 consecutive patients at 3 and 14 days after renal transplantation, and before and 1, 2, 3, 4, and 6 h after oral intake of 0.1 mg/kg tacrolimus. The area under the blood concentration/time curve (AUC) was determined by the trapezoidal method, association between blood concentration at each sampling time and AUC by Pearson's correlation coefficient, and pairs of correlation coefficients were compared by an asymptotic Wald-type test.
RESULTS: AUC varied five-fold despite near-equal dosing. Pearson's correlation coefficient for trough level, 1, 2, 3, 4, and 6 h were 0.84, 0.60, 0.81, 0.95, 0.95, and 0.94 on day 3 and 0.94, 0.69, 0.92, 0.96, 0.94, 0.92 on day 14. Three-, 4- and 6-h levels had significantly higher correlation coefficients compared to trough, 1- and 2-h levels. One-hour samples had significantly lower correlation coefficients compared to all other sampling times on day 14. The patient with the highest AUC developed nephrotoxicity despite trough levels in the desired range.
CONCLUSIONS: Two-hour levels are not superior to trough levels in tacrolimus-treated renal transplant patients. Despite good correlation between trough level and AUC, some patients may still receive nephrotoxic doses despite trough levels in the desired range. Sampling 3-6 h after oral intake may be at least as good as trough levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12147799     DOI: 10.1093/ndt/17.8.1487

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

1.  Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.

Authors:  Nayoung Han; Hwi-yeol Yun; Jin-yi Hong; In-Wha Kim; Eunhee Ji; Su Hyun Hong; Yon Su Kim; Jongwon Ha; Wan Gyoon Shin; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

2.  Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Carl M Kirkpatrick; Katie J Lee; Paul J Taylor; David W Johnson; Scott B Campbell; Diana R Leary; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

3.  A limited sampling strategy for tacrolimus in renal transplant patients.

Authors:  Binu S Mathew; Denise H Fleming; Visalakshi Jeyaseelan; Sujith J Chandy; V M Annapandian; P K Subbanna; George T John
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

4.  Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients.

Authors:  Tania Claeys; Maria Van Dyck; Rita Van Damme-Lombaerts
Journal:  Pediatr Nephrol       Date:  2009-11-03       Impact factor: 3.714

Review 5.  Once- versus twice-daily tacrolimus: are the formulations truly equivalent?

Authors:  Katherine A Barraclough; Nicole M Isbel; David W Johnson; Scott B Campbell; Christine E Staatz
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events.

Authors:  Yuen Yi Hon; Christine E Chamberlain; David E Kleiner; Michael S Ring; Douglas A Hale; Allan D Kirk; Roslyn B Mannon
Journal:  Clin Transplant       Date:  2010 Jul-Aug       Impact factor: 2.863

Review 8.  Tacrolimus: a further update of its use in the management of organ transplantation.

Authors:  Lesley J Scott; Kate McKeage; Susan J Keam; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.